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REDUCTION VENTRICULOPLASTY FOR DILATED CARDIOMYOPATHY: THE 
BATISTA PROCEDURE. Shahram Salemy, George Tellides, and John A. Elefteriades. 
Section of Cardiothoracic Surgery, Department of Surgery, Yale School of Medicine, New 
Haven, CT. 
Approximately 50% of individuals with advanced dilated cardiomyopathy die 
within one year of onset. Reduction ventriculoplasty (Batista procedure) has been 
proposed as a single discrete intervention that can restore normal cardiac chamber size and 
function in these patients. We investigated this experimental procedure in patients who 
were not candidates for the conventional option of cardiac transplantation. Nine patients (8 
male, 1 female) with advanced dilated cardiomyopathy underwent reduction 
ventriculoplasty at our institution from January, 1996 to August, 1997. Mean age was 53 
years (range 36-75) and patients were New York Heart Association (NYHA) functional 
class III (2) or IV (7). Transplantation was not indicated due to patient preference (4), 
advanced age (2), alcoholism (1), morbid obesity and pulmonary hypertension (1), and 
bronchopleural fistula with bilateral empyemas (1). Reduction ventriculoplasty was 
performed by anterior (2) or lateral (7) myocardial resection in conjunction with tricuspid 
repair (4) or mitral repair (7). Three patients died after 2 days, 11 days and 5 months due 
to heart failure. Mechanical and pharmacological support was weaned between 0-4 days in 
7 patients and one remained dobutamine dependent for 34 days. Patients were discharged 
home on postoperative day 5-43 (median=13). The 6 surviving patients are in NYHA 
functional class II (4) and III (2). Serial echocardiography revealed an increase in left 
ventricular ejection fraction from 15.3% preoperative to 32.5% at 1 year post-reduction (p< 
.0005). Multiple-gated acquisition scanning showed modest decrease in left ventricular 
end-diastolic volume from 394 ml preoperative to 328.5 ml post-reduction (p< .3). 
Reduction ventriculoplasty improves cardiac size and function with acceptable operative 
mortality and early survival in high risk patients with non-ischemic dilated cardiomyopathy 
who are not transplantation candidates. 
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REDUCTION VENTRICULOPLASTY FOR DILATED 
CARDIOMYOPATHY: THE BATISTA PROCEDURE 
BACKGROUND 
In 1999, congestive heart failure continues to be among the most common diseases 
of man. It is estimated that in the United States alone more than 3 million individuals suffer 
from congestive heart failure, with more than 400,000 new cases diagnosed per year and 
an annual mortality rate of 100,000 to 200,000.'2 Eighty percent of patients with heart 
failure are older than 65, and it is the number one discharge diagnosis in that age group. 
Despite advances in medical treatment, it continues to be a disease of high morbidity and 
mortality with several studies documenting 24-month mortalities ranging from 10%-50% 
and 48-month mortalities from 20%-60%.3" Tragically, of those with advanced heart 
disease (New York Heart Association [NYHA] Class III or IV symptoms) approximately 
50% die within one year of onset.89 Finally, it is an expensive health care issue: in 1991, 
it was estimated that the cost of medical care for patients with heart failure exceeded 5% of 
the total health care expenditure.1 
The issue for each clinician is the availability of treatment modalities, both medical 
and surgical, and which if any of these options can be utilized for an individual patient. A 
1995 symposium at the Yale School of Medicine entitled “Advanced Treatment Options for 
the Failing Left Ventricle” described the current thinking in regards to these treatment 
modalities.10 The cornerstone of medical therapy is administration of angiotensin 
converting enzyme (ACE) inhibitors due to their vasodilator effect and attenuation of 

neurohormonal compensatory mechanisms. Beta-receptor blockers also seem to be 
effective by inhibition of neurohormonal compensatory mechanisms. From a surgical 
standpoint, if the ventricular dysfunction is related to ischemic, aneurysmal, or valvular 
heart disease, then coronary artery bypass grafting, left ventricular aneurysmectomy, or 
valve replacement may be feasible. However, for many cardiomyopathy patients, 
conventional surgical techniques are not applicable. Heart transplantation yields excellent 
results but is available for only a fraction of patients with heart failure, and the limited 
supply of donor hearts has resulted in a large increase of patients on the waiting list, with 
significant pre-transplant mortality. Mechanical ventricular assist devices and 
cardiomyoplasty with skeletal muscle flaps are promising experimental approaches, but 
despite these therapeutic advances, many cardiomyopathy patients are deemed inoperable 
and rapidly deteriorate on maximum medical therapy. 
Laplace s law And the physiologic Reasoning Behind 
The Batista Procedure 
It has long been recognized that the size, shape, and thickness of the left ventricle 
are important determinants of cardiac function. Early studies applied Laplace’s law 
(tension^ pressure x radius) to the heart and concluded that ventricular enlargement resulted 
in increased wall tension for any given intraventricular pressure. Thus the dilated heart was 
found to be at a very great mechanical disadvantage compared to the heart with normal 
dimensions." Suga in 1979 confirmed the importance of ventricular dimensions on cardiac 
oxygen consumption, and Janz in 1982 validated the importance of ventricular dimensions 
on myocardial stresses.1213 Finally, clinical studies have identified cardiac enlargement as 
a primary predictor of survival in patients with cardiomyopathies of multiple etiologies.1416 
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The mechanism of progressive ventricular dilatation has been extensively 
researched in ischemic cardiomyopathy.17 Segmental infarction decreases systolic ejection, 
which increases left ventricular end-diastolic volume and pressure. This leads to increased 
wall stress, causing both infarct expansion of akinetic segments as well as volume overload 
hypertrophy of non-infarcted segments. The initial ventricular enlargement or remodeling 
after myocardial infarction is postulated to represent an adaptive mechanism to increase 
end-diastolic volume and preserve stroke volume in spite of a decreased ejection fraction.Is 
Volume-overload hypertrophy causes ventricular enlargement with an increase in 
myocardial mass and a lesser increase in wall thickness. This increase in volume with 
minimal increase in thickness is due to addition of new sarcomeres in series rather than the 
addition of new myofibrils in parallel, resulting primarily in fiber elongation.'1' The 
compensatory hypertrophy is insufficient to compensate for the increased ventricular 
volume and tension, leading to a pathophysiologic sequence of augmented systolic and 
diastolic wall stresses which stimulate further ventricular enlargement. A positive feedback 
loop or viscous cycle is created where dilation begets more dilation and promotes 
ventricular dysfunction.20 Reversal of this paradigm is clearly beneficial, and while the 
medical therapies discussed earlier do have some favorable effects, left ventricular 
aneurysmectomy and reduction ventriculoplasty (the Batista procedure) may be regarded as 
the surgical solutions for advanced ventricular enlargement which is beyond medical 
therapy. These operations can, in one discrete intervention, restore left ventricular shape 
and size, and in many patients improve cardiac function and ultimately clinical outcome. 
In order to understand the reasoning and logic surrounding reduction 
ventriculoplasty, it is essential to review its predecessor: left ventricular aneurysmectomy. 
Both have been studied by the same group at Yale, and both are based on the same 
principles described above: essentially, that restoration of proper cardiac chamber shape 
and size can lead to improvement in the function of that chamber. 
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LEFT VENTRICULAR ANEURYSMECTOMY 
Background 
It has been reported that left ventricular aneurysm occurs in 4%-20% of patients 
following transmural myocardial infarction, although these numbers are decreasing with 
thrombolytic intervention and early angioplasty.2122 The classic complications of left 
ventricular aneurysm include congestive heart failure, systemic embolization of 
intracavitary thrombus, angina, and ventricular arrhythmia. Mortality rates are high and 
variable depending on the study, ranging from 26% to 88% at 5 years depending on the 
definition of aneurysm, level of ventricular function, and extent of coronary disease.21"25 
Most pertinent to our study is that deaths from congestive heart failure and arrhythmia 
predominate in all series. 
Cooley and colleagues in 1958 were the first to suggest the concept that resection of 
a left ventricular aneurysm could produce morphological and functional benefits and lead to 
improved performance of the left ventricle.2'1 At that time, Cooley observed that ventricular 
function was “impaired by the noncontractile sac, which expands paradoxically while the 
remainder of the ventricle contracts” and that “once the structural abnormality was 
removed, restoration of the ventricle as a coordinated functional unit was accomplished and 
ventricular efficiency was improved.” There is now a wealth of data from multiple centers 
that confirms with modern imaging techniques that aneurysmectomy is an important 
modality in the treatment of the failing left ventricle. Data from Yale University will be 
discussed as well as similar results from Toronto General Hospital and the Texas Heart 
Institute.27-29 
The classical indications for surgical excision of a left ventricular aneurysm have 
been the major complications: congestive heart failure, embolization, angina, and 
arrhythmia.30 Although there has been widespread application in clinical practice and 
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extensive laboratory investigations, many basic issues regarding left ventricular 
aneurysmectomy (LVA) remain: (1) Does LVA improve or disturb ventricular morphology 
and function (does it distort the left ventricular cavity and leave a residual cavity of 
insufficient volume to permit an adequate stroke volume)? (2) What is the effect of LVA on 
symptomatic state? (3) What is the effect of LVA on long term survival? These questions 
are fundamental not only in regards to LVA but also in terms of the evolution of left 
ventricular reduction surgery from LVA to reduction ventriculoplasty. Analysis of clinical 
data and application of modem imaging techniques of multi-gated acquisition scanning 
(MUGA), intraoperative transesophageal echocardiography (ITEE), and magnetic 
resonance imaging (MRI) have helped to provide new information regarding these issues. 
Yale Experience 
Seventy-five patients underwent linear LVA at Yale-New Haven Hospital between 
July 1986 and July 1992.,() The patients ranged in age from 42 to 84 years (mean 65) and 
included 54 men and 21 women. Sixty-six aneurysms were anterior (88%) and 9 (12%) 
were posterior. Indications for surgery (multiple in some patients) included angina in 46 
(61%), congestive heart failure in 33 (44%), and ventricular arrhythmia in 41 (55%). 
Mean preoperative ejection fraction was 24.9% (range 11% to 47%). Associated open 
heart procedures included coronary artery bypass grafting in 52 patients (69%), directed 
endocardial resection in 25 (33%), and valve replacement in 4 (5%) (1 aortic and 3 mitral). 
Ten patients (13%) came to operation with the intra-aortic balloon pump (IABP) in place 
for therapeutic reasons(angina or pump failure); 39 patients (52%) had the IABP placed 
prophylactically preoperatively to provide perioperative support. 
Hospital mortality was 6.7%, with two deaths due to arrhythmia, one to pump 
failure, one to atrioventricular groove disruption (associated mitral valve replacement), and 
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one to fulminant liver failure in a patient with cirrhosis. There were no perioperative 
cerebral embolic events. Among all patients undergoing LVA, survival (including 
operative mortality figures) was 86% at one year, 80% at two years, and 64% at five years. 
Thirty-five of the 37 (95%) surviving patients who had initially presented with angina were 
improved or angina-free at the time of follow-up. In addition, mean congestive heart 
failure status (New York Heart association [NYHA] heart failure classification) improved 
from 3.04 preoperatively to 1.70 postoperatively (p< 0.0001). 
Data for comparison of preoperative and postoperative left ventricular ejection 
fraction by MUGA were available in 48 patients. Left ventricular ejection fraction 
improved from a mean of 24.9% preoperatively to 33.3% postoperatively (p< 0.0001). In 
addition, 28 intraoperative transesophageal echocardiographs (ITEE) were performed, of 
which 14 were adequate for detailed quantitative analysis. Visual assessment was 
conducted by an independent cardiac radiologist which revealed that in no case was there 
distortion of the left ventricular cavity. Visual assessment of global left ventricular 
contractility revealed immediate improvement in 92% of patients imaged. Eighty-five 
percent of patients also showed improvement in overall wall segment contractility. Finally, 
magnetic resonance imaging was conducted on 10 patients and, similar to ITEE, showed 
normalization of left ventricular size and shape after aneurysmectomy. In no case was 
distortion from normal anatomic patterns apparent. 
The data reported from the Toronto General Hospital and the Texas Heart Institute 
reported similar findings (Table 1) and so allow us to answer discretely some of the 
questions posed earlier. First, the hospital mortality from the three institutions was in the 
range of 5%, a rate consistent with results of prior studies.31 17 The three series 
demonstrated that despite advanced left ventricular dysfunction (ejection fraction in the 
range of 25%) and large proportions of patients with arrhythmia, LVA can be carried out 
with relative safety. 
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There was little morbidity directly related to LVA (such as postoperative bleeding, 
stroke, or infection of the ventricular closure site). Late complications related to 
aneurysmectomy or its repair were nonexistent. In particular, late stroke did not occur 
despite policies of not administering anticoagulants postoperatively. 
A wide range of mortality rates have been reported for patients who have been 
treated medically: from 12% to 75% at 5 years.21'25 Such a wide range of results have 
hampered comparisons with long term outcomes after LVA. The survival rates in the three 
series here do compare favorably with general survival expectations for patients who do not 
undergo surgery and who have severe left ventricular dysfunction, coronary artery disease, 
arrhythmias, and congestive heart failure. It is however impossible to draw an absolute 
conclusion without a large controlled clinical trial; such a trial may never be carried out due 
to the ample data suggesting that prognosis is poor for many patients who are treated 
medically. 
In terms of symptomatic improvement, all 3 series report discrete and significant 
improvement in exercise capacity. Patients improved at least one full NYHA class, most to 
NYHA class II or better. Also, most patients became angina free after LVA or after LVA 
and coronary artery bypass grafting. These improvements in quality of life provide 
justification for aneurysmectomy independent of survival considerations. Finally all three 
series reported show a significant, objectively determined improvement in ejection fraction 
following LVA on the order of one third or more of the preoperative ejection fraction. 
Such increases are large enough to be clinically relevant and most likely explain the 




There is a large body of evidence to suggest that myocardial infarction with infarct 
expansion or aneurysm formation leads to a vicious cycle of heart failure.18,2018-41 Both 
infarct expansion and aneurysm formation have severe effects on both the infarct zone and 
on remote, viable contractile muscle. Laplace’s law governs this phenomenon: the 
increased diameter of the ventricle after aneurysm formation leads to increased wall tension; 
this increased wall tension depresses the function of the contractile, nonaneurysmal 
segments of the left ventricle.42 This process, coupled with the loss of stroke volume 
consumed in expanding the dyskinetic aneurysmal wall in systole, leads to congestive heart 
failure. The congestive heart failure leads to fluid retention and further left ventricular 
dilation, and the viscous cycle continues. 
Extension of Indications for Aneurysmectomy 
Given this understanding as well as the findings of their LVAs, the Yale authors 
conclude that LVA constitutes an important therapeutic tool that can, in one discrete 
intervention, bring left ventricular diameter back toward normal, lower wall tension and 
hence interrupt the lethal vicious cycle. Secondly, they contend that mere presence of an 
aneurysm in a patient undergoing revascularization merits LVA (even without the classic 
indications of congestive heart failure, emboli, angina, or arrhythmia) provided that the 
aneurysm is discrete and at least moderate in size and that ventricular function outside the 
infarct zone is reasonably preserved (the finding of high filling pressures in the 
catheterization laboratory, even in the absence of overt clinical heart failure, provides 
further support to resect the aneurysm). Finally, the authors believe that LVA may be 
indicated despite the absence of the classic symptoms previously mentioned in patients not 
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undergoing surgery for other reasons. They believe that patients with aneurysms should be 
serially followed by echocardiography and nuclear imaging and the undergo elective LVA 
to prevent decompensation should there be progressive left ventricular enlargement or 
decreased ejection fraction. In short, the authors contend that the documented beneficial 
effects of LVA justify such broader indications for utilization. 
Relevance to Reduction Ventriculoplasty 
While these data are significant in and of themselves, their relevance extends into 
the realm of reduction ventriculoplasty. Specifically, (1) the pathophysiologic mechanisms 
of left ventricular dilatation that are based on Laplace’s law, (2) the fundamental of a 
vicious cycle of left ventricular dilatation and heart failure, and (3) the notion that this cycle 
can be interrupted in one discrete intervention, with acceptable immediate and long-term 
mobidity and mortality, in patients who otherwise have a dismal prognosis. The next 
section will outline the protocol and results of our clinical trial studying the utility and 
efficacy of reduction ventriculoplasty for dilated cardiomyopathy. 
Clinical Protocol for reduction ventriculoplasty 
Hypothesis 
The hypothesis to be tested is that reduction ventriculoplasty is a relatively safe 
operation and will result in a significant improvement in cardiac structure (left ventricular 
end-systolic and end-diastolic dimensions) and function (ejection fraction), functional 
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status (New York Heart Association [NYHA] class I-IV) and quality of life (QOL 
questionnaire) in patients with advanced dilated cardiomyopathy as compared to the 
patients’ preoperative status on maximum medical therapy. Survival was also compared to 
historical control patients on maximum medical therapy. The essential principle of the 
reduction ventriculoplasty operation is that restoration of a normal left ventricular volume to 
mass ratio will improve the function of the remaining myocardium in patients with 
advanced dilated cardiomyopathy in the absence of a discrete aneurysm. 
Student’s Role 
The role of the student in this study was a clear and distinct one. Unlike a chart 
review, the student was involved from the onset of the project in a prospective fashion. He 
was instrumental in structuring the planning of the investigation including the creation of 
patient inclusion and exclusion guidelines, questionairres, and follow-up. In addition, he 
studied both the operative procedure and attended operations and was responsible for the 
entire data analysis which he provided to the advisor as new data points became available. 
Also, it is worth noting that the student completed all of these tasks over the course of three 
years in which there were no published data on the topic. Finally, the student was 
responsible for helping publish results of the first experience with the Batista procedure in 
New England.41 
Protocol 
Nine patients with advanced heart failure from dilated cardiomyopathy who agreed 
to participate in this study and from whom informed consent was obtained had specific 
evaluations and investigations and underwent reduction ventriculoplasty in addition to any 
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necessary conventional cardiac surgery. Clinical assessment and investigations of patients 
continued for up to 24 months. 
Reduction ventriculoplasty was performed according to the method of Dr. Randas 
Batista.44 The technique, in brief, was as follows. A median sternotomy was made and 
the pericardium opened. The patients were systemically heparinized and cannulated for 
bypass. Normothermic cardiopulmonary bypass was instituted and the heart kept beating 
by immediate defibrillation as required and use of potassium injection into the aortic root. 
The heart was continuously perfused and no aortic cross-clamping or cardioplegia was 
utilized. The lateral ventricular wall was sharply incised near the apex of the heart between 
obtuse marginal artery branches. The incision was continued towards the base of the heart 
close to the posteromedial papillary muscle under direct vision. The incision was 
completed by carefully excising the ventricular wall close to the anterolateral papillary 
muscle and across the base about an inch from the circumflex artery. The wedge-to-oval 
shaped specimen was removed and further tailoring of the resection margins performed as 
necessary. Hemostasis of bleeding epicardial artery branches was obtained by cautery. 
Any thrombus was carefully removed. The ventriculotomy incision was closed with two 
layers of running prolene sutures without the use of reinforcing felt pledget strips. The 
patient was weaned off bypass with liberal use of sodium nitroprusside for afterload 
reduction and isoproterenol for inotropic stimulation. Hemostasis was confirmed and the 
chest closed in the usual fashion. 
Associated conventional cardiac operations were performed as necessary. 
Tricuspid valvuloplasty was done under total cardiopulmonary bypass prior to reduction 
ventriculoplasty. Mitral valve repair could be carried out through the ventriculotomy 
incision as required. Aortic valve repair and replacement or coronary artery bypass grafting 
could be done conventionally after the reduction ventriculoplasty. Aortic cross-clamping 
and continuous warm perfusion through a coronary sinus catheter or antegrade and 
retrograde cold cardioplegia were utilized for these additional procedures. 
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Patients were evaluated preoperatively and at standard intervals postoperatively. 
Preoperative evaluation included consultation by the heart failure service and, when 
necessary, by the electrophysiology service. Clinical assessment and investigations were 
conducted at intervals as specified in Table 2. This included a history of symptoms, 
medications and hospitalizations, NYHA functional class, quality of life questionnaire, 
blood tests as specified, pulmonary function tests, chest roentgenograms, 
electrocardiograms, right and left heart catheterization, transthoracic echocardiogram, 
transesophageal echocardiogram, multiple-gated acquisition (MUGA) scanning, chest 
MRI, exercise test and 6 minute walk. The patients were analyzed and the data evaluated 
using statistical tools, such as the paired t test, in order to assess the significance of the 
differences in variables before and after reduction ventriculoplasty. 
Subject Population 
Of significance is that patients who were not candidates for cardiac transplantation 
(in particular the elderly or patients with systemic disease processes) were still considered 
for reduction ventriculoplasty. In addition, concomitant bypass or valve cardiac surgery 
did not exclude patients from reduction ventriculoplasty. 
Patient Inclusion Criteria 
• Advanced heart failure due to dilated cardiomyopathy on maximal medical therapy 
• NYHA Class III or IV functional status 
• AGE > or = 18 years old 
• Males or nonpregnant females 
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• Left ventricular end-diastolic dimension > 5.5 cm 
• Left ventricular ejection fraction < 30% 
• Peak oxygen consumption (V02) > 10 and < 22 ml/kg/minute 
• Geographic availability for follow-up 
Patient Exclusion Criteria 
• Age < 18 years old 
• Pregnant females 
• Cardiac reasons if there was: 
• cardiogenic shock with systolic pressure < 90 mm Hg 
• dependence on intravenous inotropic agents 
• uncontrolled hypertension with diastolic pressure > 95 mm Hg on medications 
• severe pulmonary artery hypertension with systolic pressure > 60 mm Hg 
• severe persistent arrhythmias despite optimal medical treatment 
• cardiac arrest, myocardial infarction, or angioplasty within 3 months 
• previous cardiac surgery 
• hypertrophic cardiomyopathy 
• participation in concurrent cardiac investigational drug study 
• Pulmonary reasons if the forced vital capacity was < 50% of predicted value 




• Hepatic reasons if hyperbilirubinemia > 3 mg/dl, active hepatitis or severe cirrhosis 
• Nutritional cachexia with serum albumin < 2.5 gm/dl 
• Neurological reasons if dense stroke or severe dysfunction 
• Unresolved psychiatric disease or drug abuse 
• Clinically significant multi-organ dysfunction 
• Any non-cardiac disease preventing or limiting survival, exercise ability or 
rehabilitation 
• Patient unable or unwilling to comply with the study requirements or protocol 
DATA 
Nine patients (8 male, 1 female) underwent reduction ventriculoplasty at our 
institution from January 1996 to August 1997 (Table 3). All were diagnosed with 
advanced, idiopathic cardiomyopathy, with NYHA functional class III (2) or IV (7). Mean 
age was 53 (range 36-75), and had the following contraindications to cardiac 
transplantation: patient preference (4), advanced age (2), alcoholism (1), morbid obesity 
and pulmonary hypertension (1), and bronchopleural fistula with bilateral empyemas (1). 
Three were inotrope dependent, 1 was intra-aortic balloon pump (IABP) dependent, and 3 
were Intensive Care Unit dependent. 
Preoperatively, the mean left ventricular ejection fraction (EF) by echocardiography 
(ECHO) was 15.3% (range 9%-23%, standard deviation (SD) ±5.12) and by multiple¬ 
gated acquisition scan (MUGA) was 16.9% (range 7%-31%, SD ± 8.96) (Table 3). Mean 
left ventricular end-diastolic dimension (LVEDD) by ECHO was 7.46 cm (range 6.3 cm- 
9.6 cm, SD ± .97) and mean left ventricular end-diastolic volume (LVEDV) by MUGA 
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was 394 ml (range 320 ml- 470 ml, SD ± 47.14). All but one of the nine patients had 
preoperative evidence of valvular disease by ECHO. 
Partial left ventriculectomy was performed by anterior (2) or lateral (7) myocardial 
resection in conjunction with tricuspid valve repair (4) and mitral valve repair (7) (Table 4). 
Three patients died after 2 days, 11 days and 5 months due to heart failure. Mechanical and 
pharmacological support was weaned between post-operative day 0-4 in 7 patients; one 
patient remained dobutamine dependent for 34 days. Patients were discharged home on 
postoperative day 5-43 (mean= 13, SD ± 12.3). 
Serial echocardiography showed a decrease in mean left ventricular end-diastolic 
dimension from 7.46 cm preoperatively (n=9, SD ± .97) to 6.46 cm at 2 weeks post¬ 
reduction (n=8, p< 0.0075, SD ± .46), 6.90 cm at 3 months post-reduction (n=4, p< 0.15, 
SD ± 1.43), and 6.75 cm at 1 year post-reduction (n=2, p< 0.30, SD ± 1.63) (Figure 1, 
Table 5). Echocardiography also revealed an increase in mean left ventricular ejection 
fraction from 15.33% preoperatively (n=9, SD ±5.12) to 26.00% at 2 weeks 
postoperatively (n=5, p< 0.025, SD ± 10.29), 26.25% at 3 months postoperatively (n=4, 
p< 0.10, SD ± 3.78) and 32.5% at 1 year post-reduction (n=2, p< 0.0005, SD ± 3.54) 
(Figure 2). 
Serial MUGA scans also reported an increase in mean left ventricular ejection 
fraction from 16.89% preoperatively (n=9, SD ± 8.96) to 21.86% at 2 weeks post¬ 
reduction (n=7, p< 0.15, SD ± 8.80), 26.25% at 3 months post-reduction (n=4, p< 0.10, 
SD ± 13.77), and 30.5% at 1 year post-reduction (n=2, p< 0.005, SD ±9.19) (Figure 3). 
Feft ventricular end-diastolic volume decreased from a mean value of 393.88 ml 
preoperatively (n=8, SD ± 47.14) to 374 ml at 2 weeks post-reduction (n=4, p< 0.5, SD ± 
160.63), 358.33 ml at 3 months post-reduction (n=3, p< 0.3, SD ± 107.34) and 328.5 ml 
at 1 year post-reduction (n=2, p< 0.3, SD ± 118.09) (Figure 4). Most importantly from a 
quality of life standpoint, the 6 surviving patients are in NYHA class II (4) or III (2) (mean 




This section should be approached in the manner in which the operation was 
conceived: beginning with a theoretical and mathematical discussion, which eventually 
leads to a discussion of our data and of that from other centers. 
Mathematical Analysis and Critique 
Laplace’s law is as follows: 
P = 2 CT :|: h (equation 1) or T= P * R (equation 2) 
R 
Where h is the wall thickness, a is the wall stress, P is the transmural pressure, R is the 
cavitary radius, and T is tension. Regardless of its form, this law states that the larger the 
cavity (R) and the higher the pressure of the fluid it contains (P), the more the tension (T) 
on the wall. For the heart, the greater the tension, the greater the force necessary for 
ejection, thus the greater the need for muscular compensation. This concept is better 
understood in terms of the pathology behind dilated cardiomyopathy. As the left 
ventricular chamber enlarges, peak systolic wall stress increases (by the law of Laplace) 
which then causes myocardial hypertrophy of sufficient magnitude to normalize the systolic 
stress.45 The basic principle of the Batista procedure for dilated cardiomyopathy is not to 
reduce the mass of the ventricle but to reduce the size of the chamber of the dilated 
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ventricle, thus to reduce the wall stress of the ventricle and to prevent further myocardial 
hypertrophy and ultimate heart failure, the “vicious cycle” that was discussed earlier. 
The reduction of chamber volume, however, is achieved only at the expense of 
muscle excision. Despite the increase in myocardial mass secondary to chamber 
enlargement and increased systolic wall stress, the myocardial stress is always higher in 
patients with dilated cardiomyopathy .454y According to a principle defined by Grant, 
Greene, and Bunnell and supported by others the normal mass to chamber volume ratio 
should be maintained in dilated cardiomyopathy.4"46 50 Kennedy and associates calculated 
both mean normal values of left ventricular mass/left ventricular end-systolic and end- 
diastolic volume ratios (LVM/LVESV and LVM/LVEDV) as well as mean myocardial wall 
stress in survivors and nonsurvivors with dilated cardiomyopathy using the following 
equation:485'52 
CF = 1.335 * Plv(l + [3V|v/Vm]) (equation 3) 
where Plv is instantaneous or mean left ventricular systolic pressure, Vm is the volume of 
the myocardium, Vlv is LVESV, and o is calculated systolic stress. The mean myocardial 
wall stress in survivors and nonsurvivors with dilated cardiomyopathy was 541 and 590 
kdynes/cm2, respectively. The calculated value of mean LVM/LVESV ratio in survivors 
and nonsurvivors with dilated cardiomyopathy was 1.36 and 1.06, respectively. Similarly, 
in another report concerning patients with compensated dilated cardiomyopathy, the 
calculated mean LVM/LVESV ratio (1.8) was higher than that (1.09) in patients with 
decompensated dilated cardiomyopathy.47 These findings suggest that the previously stated 
hypothesis is not valid: ventricular mass does increase but not proportionally with the 
increase in chamber volume (which explains the dilation of the ventricle) and not to the 
degree required to normalize the systolic stress (hence eventual cardiac decompensation). 
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We can now use these mathematic and physiologic principles as evidence for the 
potential benefits that volume reduction surgery can provide. Chanda et al. illustrates the 
importance of ventricular mass in reduction of systolic stress using the above formula in the 
following example.^ In a normal patient with a Plv of 122 mm Hg, a Vlv of 45 ml, and an 
LVM of 164 gm, the calculated systolic stress a is 306 kdyne/cm232 In a patient with 
decompensated dilated cardiomyopathy with Plv= 105 mm Hg, Vlv= 300 ml, and 
LVM=480 gm, the calculated systolic stress would be 414 kdyne/cm2. In this patient, to 
keep the systolic stress 306 kdyne/cm2, an additional 338 gm (i.e. total LVM of 818 gm) 
would be necessary. With the reduction of LVESV from 300 to 150 ml and LVM from 
480 to 300 gm, the left ventricular systolic stress would be reduced from 414 to 359 
kdyne/cm2, if the Plv were to remain 105 mm Hg. This example helps illustrate that in 
dilated cardiomyopathy, surgical intervention directed to chamber volume reduction, even 
at the expense of mass reduction, would decrease the myocardial wall stress. 
It must be made clear that a reduction in stress does not uniformly equate with a 
physiologic benefit. For example, removing half of the ventricle of a normal heart would 
result in a decrease in wall stress, but would clearly not improve its function. The issue 
then is precisely how dilated must the ventricle be and how much ventricular mass must be 
removed in order for there to be a beneficial effect? From a vigorous mathematical point of 
view, the answer is yet to be provided. 
Another example can help illustrate the point.54 In nature, muscle fibers can only 
generate a certain maximum amount of force per unit surface area (Gmax). In order for a 
heart to generate a non-zero stroke volume, intraventricular pressure must exceed a minimal 
systemic systolic pressure (Pmin). On the basis of equation 1, for a sufficiently dilated 
ventricle: 

R > 2 * (Tmax * h 
min 
Therefore, as the ventricle continues to dilate (R increases) stroke volume approaches zero. 
In this limiting case, resection of ventricular mass, by reducing R while keeping h constant, 
will increase stroke volume to a non-zero value. It follows that if ventricular function were 
occurring purely on a geometric basis (due to dilation with normal intrinsic fiber 
contractility), an appropriate resection, such that R/h were corrected to normal, would 
mathematically lead to a return to normal function. 
In short, there are clearly extreme theoretical cases in which the Batista procedure 
will lead to an increase in function in absolute terms. There are other extremes at which 
function will be worsened, but in both cases stress can be reduced. Therefore, 
mathematical stress reduction alone does not imply any particular acute effect on function 
and therefore not on clinical improvement. With this understanding of the mathematics 
involved, it is clear that clinical data is required in order to truly assess the efficacy of 
volume reduction surgery. 
The Yale Data 
A few points regarding our findings must be made. Firstly, although nine patients 
underwent the procedure, it is difficult to accurately assess how many patients refused the 
operation as well as how many patients were denied the operation because they did not 
meet protocol criteria. Multiple patients evaluated in our offices fell into both categories, 
but the exact numbers are unclear. 
Secondly, there was no appreciable differences in long-term outcome among 
patients who had refused transplantation compared to those who were simply not 
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transplantation candidates. Three of the four Batista patients who refused transplantation 
were alive at one year post-operation, compared to three of the five Batista patients who 
had not been transplantion candidates. In addition, of the patients alive at one year, there 
was no difference in cardiac functional class (see Table 5). 
Thirdly, although it would be helpful to estimate the theoretical mortality of these 
patients without surgery, it is extremely difficult to do so. This is an unfortunate but 
inherent problem to experimental surgical treatments for congestive heart failure, as most if 
not all studies cannot be randomized. In addition, with such experimental surgery, the 
number of patients involved is usually quite low and decreases further as follow-up time 
increases, thus making accurate clear judgement of benefit less and less objective. It 
should be made clear however that although the number of patients involved in our study 
appears small, it is quite respectable compared to other academic centers studying this 
fledgling operation. 
In terms of the significance of our data, a few points come to the forefront. First, it 
was clear ejection fraction was increased as evaluated by both echocardiography (from 
15.33% pre-operative to 32.5% post-operative, see figure 2) and MUGA scan (16.89% 
pre-operative to 30.5% 1 year post-operative, see figure 3). In addition, MUGA scan also 
revealed a modest reduction in ventricular chamber size as shown in figure 4. In analyzing 
such results however, the most siginificant indicator (both statistically and clinically) of the 
efficacy of this intervention must be the reduction in New York Heart Association 
functional class, most patients being at class II or III at one year post-reduction. This 
indicator of the patients’ quality of life, beyond any other measured outcome, hints to us 
that the operation had quite a postive impact in the lives of some patients. 
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Batista Procedure Experience at Other Centers 
The application of volume reduction surgery to idiopathic dilated cardiomyopathy 
was first introduced by Dr. Randas Batista of Brazil. Although he has reportedly 
performed the operation on over 200 patients, his follow-up evaluation is lacking. His data 
along with that of the cardiothoracic surgery department at Buffalo was recently reported.' '1 
Their combined data involved 120 patients with end-stage cardiomyopathy, most of whom 
were in New York Heart Association (NYHA) class IV. It should be mentioned that 51 of 
these patients also underwent a valve repair procedure, and that no patients who were 
awaiting cardiac transplantation were offered the operation, thus selecting for patients with 
more advanced disease. They reported a 30-day mortality of 22% and a 2-year survival of 
55%, with most of the surviving patients either in NYHA class I (57%) or class II (33%). 
They did report difficulty in obtaining information concerning the Brazilian patients other 
than the cause of the disease, procedures performed, and crude operative mortality. In 
addition, they admited that due to limited follow-up. it was not possible to make 
conclusions regarding long-term outcome of the Brazilian patients. The experience at 
Buffalo did however suggest that the procedure had merits for selected patients, such as 
those with dilated cardiomyopathy of a viral or idiopathic cause with or without valvular 
involvement. 
Dr. James McCarthy at the Cleveland Clinic has also studied reduction 
ventriculoplasty on 57 consecutive patients, the majority of which (95%) had heart failure 
secondary to idiopathic dilation.56 All of the patients were either in NYHA class III or IV, 
and 95% of the patients were awaiting heart transplantation. Notably, 55 of the patients 
also underwent mitral valve repair at the time of reduction. They reported at 3 months an 
increase in left ventricular ejection fraction (14% to 23%), a reduction of left ventricular 
end-diastolic volume (254 ml to 179 ml) and diameter (8.4 cm to 6.3 cm). Cardiac index, 

however, did not change (2.2 1/min per nr). On follow-up, there were 7 late deaths 
(including 3 sudden deaths) giving an actuarial survival of 82% at 1 year. 
G.D. Angelini and colleagues from Bristol conducted the Batista procedure on 14 
patients, 7 of which also had a mitral valve repair operation."' This group was different 
from the Cleveland group in that older patients, non-transplant candidates, and ischemic 
and valvular patients as well as those with cardiomyopathy were operated upon; this was 
also the case in the Brazil/Buffalo report. All but 3 of the patients survived the operation 
and one died 3 months later. The others, however, had a significant increase in cardiac 
index, from 1.91 to 2.27 L/min. per nr. The authors concluded that the operation might be 
indicated not only in patients with cardiomyopathy but also in those with ischemic heart 
disease and in non-transplant candidates. 
Synthesis of Clinical Data 
Two points regarding these findings must be addressed. First, when analyzing 
these results it is important to consider the effect of mitral valve repair on outcome, as the 
majority of patients in our series as well as those in the Cleveland series and many in the 
Buffalo/Brazil and Bristol series had mitral valve repair. Bolling and co-authors have 
demonstrated clinical improvement in patients with end-stage cardiomyopathy after mitral 
valve repair alone and reported an actuarial 1-year survival of 75%.5S This leads to the 
valid question of whether or not the positive results are due to the mitral valve repairs. 
Interpreting the effect of the repair in our series is difficult, as those patients with the 
mildest mitral regurgitation (see Tables 3 and 5) were either deceased or lost to follow-up. 
However, in the Cleveland series 27% of their patients had only 0-2+ mitral regurgitation 
and yet showed significant clinical improvement. This effect is therefore unlikely to be due 
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to the mitral repair alone. This leads us to believe that the beneficial effects of reduction 
ventriculoplasty and mitral repair are complementary. 
Second, when analyzing the data from the Cleveland and Bristol experiences, one 
sees a significant improvement in cardiac index in the Bristol patients but not in the 
Cleveland ones.5" This difference is probably due to the heterogeneity of the patients in 
Bristol, with some having ischemic heart disease and localized ventricular dysfunction, 
which are known to improve after resection of the area. Also, most of the patients in the 
Bristol group underwent not only mitral valve repair but also another associated procedure, 
such as coronary artery bypass, tricuspid valve repair, or aortic valve replacement. Since 
any of these procedures alone, without surgical ventricular reduction, have been associated 
with remarkable functional improvement and spontaneous left ventricular reduction, it is 
not possible to determine whether one of the valve procedures, the coronary 
revascularization, or the ventricular reduction was the most beneficial and specific 
intervention.58 60 This concept holds true for all of the reduction ventriculoplasty series to 
date. 
Conclusions 
It is clear that congestive heart failure continues to be among the most prevalent of 
human afflictions and is responsible for a large portion of our yearly national health care 
expenditure. It is also clear that many of these patients are on maximum medical therapy 
and have dismal prognoses without cardiac transplantation, which is an extremely limited 
resource and for which many of these patients simply are not candidates. With this 
understanding, a surgical procedure that could in one discreet intervention reduce the 
volume of a dilated heart and improve function both by objective data and by clinical criteria 
is an attractive proposition. Our data as well as that from other centers have a common 
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dilemma: while without question reduction ventriculoplasty provides improved cardiac 
function and quality of life for certain individuals with very advanced disease, predicting 
exactly which of these individuals will benefit from the procedure has not been elucidated. 
Indeed, no center to date has been able to accurately predict which patients will benefit from 
the operation and which will not. A more careful analysis is needed that examines multiple 
absolute criteria, in particular to specify which cardiomyopathic etiologies and which levels 
of dilatation can be expected to gain benefit from reduction surgery. 
The current thinking regarding the various surgical interventions for dilated 
cardiomyopathy stand is as follows. Linear aneurysmectomy is reserved for patients with 
an isolated ischemic aneurysm. Skeletal muscle flap utilization, while once quite 
promising, have been terminated by the Food and Drug Administration (FDA) due to lack 
of a clear cut benefit. Mechanical assist devices have been FDA-approved as a bridge to 
cardiac transplantation. This latest approval has to a certain extent dimmed the enthusiasm 
surrounding the role of the Batista procedure as the possible primary intervention to bridge 
cardiomyopathy patients to eventual transplantation. Therefore, while the best 
recommendation for transplantation candidates is either a transplant or a mechanical heart 
serving as a temporary bridge to transplantation, if these patients refuse or have a 
contraindication to the transplant, the Batista procedure can be utilized. Thus, reduction 
ventriculoplasty will continue to remain an operation with acceptable mortality reserved for 
patients with advanced disease and on maximum medical therapy without improvement 
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